XXXX -induced severe cutaneous adverse reactions.

@entity1 @entity137 @entity6715 @entity1092 @entity2052 @entity7586 @entity2812
PURPOSE: We systematically reviewed and analyzed published and unpublished cases of @entity6715 ( @entity6715 ), or @entity137 ( @entity137 ) associated with @entity2812 (LTG) therapy to identify characteristics of these reactions. METHODS: We performed a MEDLINE search (January 1985 to April 1998) and citation tracking for published reports. In addition, reports were requested from the Uppsala Monitoring Centre of the World Health Organization (WHO). Published and WHO cases of LTG-associated @entity6715 or @entity137 were included if the causal relationship was assessed as either possible, probable, or definite. RESULTS: We identified a total of 57 cases (43 cases of @entity6715 , 14 cases of @entity137 ), of which 13 (23%) were published. Cases in the @entity6715 group were significantly younger than in the @entity137 group (21 years vs. 31 years). The median time to onset (17 days for @entity6715 and @entity137 ) and the median dosage at onset (50 mg vs. 87.5 mg) for @entity6715 and @entity137 did not differ significantly. Concomitant use of @entity1092 ( @entity2052 ) was reported in 74% of the @entity6715 cases and 64% of the @entity137 cases. In three cases, @entity137 was the cutaneous manifestation of the antiepileptic drug @entity7586 (AHS). CONCLUSIONS: The main features of severe cutaneous drug reactions, such as dosage, onset, and concomitant @entity2052 use, do not differ in @entity1 with LTG-induced @entity6715 or @entity137 . @entity6715 or @entity137 may also be the cutaneous manifestations of LTG-induced AHS. Further epidemiologic studies are needed to identify the incidence of severe LTG-induced cutaneous adverse reactions and the relative risk compared with other AEDs.
